How to Buy Gilead Sciences Stock
Gilead Sciences Inc
Gilead Sciences, Inc. , a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
Gilead Sciences stock last closed at $143.93, down 0.83% from the previous day, and has increased 24.03% in one year. It has overperformed other stocks in the Drug Manufacturers - General industry by 0.08 percentage points. Gilead Sciences stock is currently +54.15% from its 52-week low of $93.37, and -8.49% from its 52-week high of $157.29.
There are currently 1.24B GILD shares outstanding. The market value of GILD is $178.68B. In the last 24 hours, 4.81M GILD shares were traded.
How to Buy Gilead Sciences Stock
Not sure how to invest in Gilead Sciences stock? Here's how.
- Decide where to buy Gilead Sciences stock: You need to pick an online brokerage, but don't worry - we've researched dozens of online brokerages and apps to help you decide where to buy Gilead Sciences stock.
- Sign up for your brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've found.
- Deposit funds into your brokerage account: Choose your method of payment and add your details.
- Analyze Gilead Sciences stock: The Gilead Sciences ticker symbol is GILD. Is Gilead Sciences stock a good investment? Should you buy shares of GILD? How do GILD's underlying business fundamentals look? Do top analysts think Gilead Sciences is a good buy? Why has GILD's stock price moved recently? (Hint: Our stock analysis website can help you figure out if GILD is a good stock to buy).
- Execute your GILD purchase: Decide if you will purchase GILD shares at the current market price or use a limit order to buy GILD shares at a specific price.
- Keep tabs on your investment in GILD: Create a watchlist to track your position in Gilead Sciences shares.
Step 1: Decide where to buy Gilead Sciences stock
You will need an online brokerage account to access the NASDAQ market and buy GILD stock.
Our favorite brokerage: eToro
Based on our research, eToro is the best brokerage. eToro gives you:
- Invest in stocks with 0% commissions: Invest without commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still buy the stock.
- Access to world markets: From Technology to Real Estate, New York to Shanghai (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's top exchanges.
- Social investing: eToro offers a community with more than 20 million users around the world. Talk to, learn from, and copy the unique crypto portfolios of other investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other assets: Such as ETFs and cryptos.
Get $10 towards your stock purchase by creating an account with eToro now. This offer is only for US users.
Open eToro AccountStep 2: Sign up for your brokerage account
Now that you've picked the right brokerage, you need to fill out some personal details so you can invest in GILD today.
How to Set Up a New Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Input your personal details to open a new brokerage account.
- Submit your details by hitting the "Create Account" button. Get started with eToro today
Step 3: Deposit funds into your brokerage account
Now that you've filled out your info on one of the most highly reviewed stock market apps, you can securely and quickly fund your account:
Watch the tutorial below to see the process of transferring funds into your new investment account.
Step 4: Analyze Gilead Sciences stock
After you have decided on the best place to buy Gilead Sciences stock, it's crucial to research their stock prior to buying, so you truly wrap your head around the risk and opportunity.
Gilead Sciences stock data
Gilead Sciences Overview
WallStreetZen was designed to help everyday investors do more accurate fundamental analysis in less time.
You can see all of the due diligence checks on GILD's stock page.
Is GILD stock undervalued?
You can use many financial metrics, analyses, models, and charts to gauge GILD's intrinsic value.
Using relative valuations measures:
- GILD may be undervalued based on its P/E ratio of 21.04x, relative to Drug Manufacturers - General industry P/E ratio of 34.96x
- GILD may be overvalued based on its P/B ratio of 7.87x, relative to Drug Manufacturers - General industry P/B ratio of 7.14x
- GILD could be overvalued based on its PEG ratio of 1.31x
You can access additional valuation analysis on GILD's stock here.
How do GILD Financials look?
Positive Health Checks:
- GILD's operating cash flow of $10.02B allows it to safely service it's debt of $24.94B.
- GILD profit margin has gone up from 1.7% to 28.9% in the past year.
- There are more short-term assets than short-term liabilities on the GILD balance sheet.
- GILD earnings of $10.82B is not enough to cover its interest payments.
- Total GILD debt is lower than 5 years ago, relative to shareholder equity.
Negative Health Checks:
- There are more long-term liabilities than short-term assets on the GILD balance sheet.
- GILD has a relatively high debt to equity ratio of 1.6.
Is it a good time to buy Gilead Sciences stock, according to analysts?
Out of 13 Wall Street analysts who monitor GILD, the consensus analyst rating on Gilead Sciences is a Strong Buy
It's important to keep in mind that analyst ratings are not recommendations, nor are they investment advice.
Latest GILD Analyst Forecasts
Carter Gould, a top 11% analyst from Cantor Fitzgerald maintains GILD with a strong buy rating and raises their GILD price target from $135.00 to $155.00, on Feb 11, 2026.
Cantor Fitzgerald's Carter Gould raised their price target on Gilead Sciences (NASDAQ: GILD) by 14.8% from $135 to $155 on 2026/02/11. The analyst maintained their Strong Buy rating on the stock.
Gilead Sciences reported its Q4 and FY 2025 earnings.
Raising their price target, Gould urged readers not to over-react to the post-print dip actuated by management's $800M 2026 revenue guidance for Yeztugo, which missed consensus but "appears to represent a floor," and is inconsistent with the $1B consensus based on clear upside tailwinds.
Looking ahead, the analyst said Gilead Sciences management's broader base business guidance was also solid, with stronger-than-expected HIV growth predicted and, notably, improved confidence regarding Trodelvy.
Earnings Report
Gilead Sciences reported:
For Q4 2025:
- EPS of $1.86, which beat the Zacks Consensus Estimate of $1.83 but missed Q4 2024's $1.90.
- Revenue of $7.9B, which beat the Zacks Consensus Estimate of $7.6B and was up 5% Y/Y.
For FY 2025:
- EPS of $8.15, up from FY 2024's $4.62.
- Revenue of $29.4B, up 2% Y/Y.
For FY 2026, management guided:
- EPS of $8.45 to $8.85.
- Total product revenue, excluding Veklury, of $29 B to $29.4B.
- Total Veklury revenue of $600M.
Chairman & CEO Daniel O’Day commented: “Our fourth quarter and full-year results close out a very strong year for Gilead overall, including the successful U.S. launch of Yeztugo, the world’s first twice-yearly HIV prevention therapy, and continued growth for Biktarvy and Descovy.
“In 2026, our potential new launches include two cancer therapies and an additional HIV treatment option, and we look forward to building on the launches of Yeztugo and Livdelzi for liver disease.
"As we continue to increase our positive impact onhealthcare, Gilead is well-positioned for continued growth in 2026 and beyond.”
Louis Chen, a bottom 18% analyst from ScotiaBank maintains GILD with a buy rating and raises their GILD price target from $140.00 to $177.00, on Feb 11, 2026.
Geoff Meacham, a top 12% analyst from Citigroup maintains GILD with a strong buy rating and raises their GILD price target from $140.00 to $156.00, on Jan 27, 2026.
Michael Yee, a top 16% analyst from UBS maintains GILD with a strong buy rating and raises their GILD price target from $145.00 to $155.00, on Jan 26, 2026.
Matthew Harrison, a top 22% analyst from Morgan Stanley maintains GILD with a strong buy rating and lowers their GILD price target from $151.00 to $150.00, on Jan 13, 2026.
You can dive deeper into what analysts are saying on the Gilead Sciences stock forecast page.
GILD Momentum
GILD Revenue
Last year, GILD earnings were $8.51B. In the past 5 year, GILD's earnings have increased by 132.82% per year. This was faster than the Drug Manufacturers - General industry average of 19.55%.
Last year, GILD revenue was $29.44B. In the past 5 year, GILD's revenue has gone up by 3.58% per year. This was slower than the Drug Manufacturers - General industry average of 10.06%.
Dive into GILD's earnings and revenue performance here.
What are GILD insiders up to?
In the last year, insiders at GILD have sold more shares than they have bought.
Daniel Patrick Oday, Chairman CEO of GILD, was the latest GILD insider to sell. They sold $501,385.84 worth of GILD stock on Feb 27, 2026.
Get more info about who owns GILD stock here.
Can I get consistent income from GILD stock?
Gilead Sciences pays a dividend of 2.2%, compared to the Drug Manufacturers - General industry's average dividend yield of 2.66%. If you owned $1,000 worth of GILD stock, you would have been paid $21.96 last year.
Gilead Sciences dividend payments have consistently grown over the past decade and have remained stable.
Find more info about Gilead Sciences dividend yield and history here.
GILD Social Trading Data
One of the primary reasons eToro is our favorite brokerage is because of its social trading community.
Click below to find out what other community members have to say.
Step 5: Execute your GILD purchase
There are two primary options:
- Market order: A market order is an order to buy or sell a security at the best possible price.
Market orders are usually fine. - Limit order: A limit order lets you buy or sell a stock at a specific price (or better).
If you want to make sure you're buying or selling at a given price, place a limit order.
Press the Open Trade button and your broker will execute your order.
If you want additional assistance buying stocks on eToro, click the helpful video below:
Step 6: Keep tabs on your investment in GILD
Now that you own some GILD stock, you'll want to stay up-to-date on your new stock purchase.
Put GILD on a watchlist to track your GILD stock.
GILD Feed
How to Buy Stock in Gilead Sciences
To reiterate, here are the 6 steps to buy stock in Gilead Sciences:
- Decide where to buy Gilead Sciences stock
- Sign up for your brokerage account
- Deposit funds into your brokerage account
- Analyze Gilead Sciences stock
- Execute your GILD purchase
- Keep tabs on your investment in GILD
If you require a brokerage account, eToro is our recommended option.
Get Started with eToro TodayIf you would like to get updates on your investment in Gilead Sciences, create your watchlist below.
Trending Stock Buying Guides
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.